Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SGHT
Upturn stock ratingUpturn stock rating

Sight Sciences Inc (SGHT)

Upturn stock ratingUpturn stock rating
$4.25
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SGHT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $4.27

1 Year Target Price $4.27

Analysts Price Target For last 52 week
$4.27 Target price
52w Low $2.03
Current$4.25
52w High $7.05

Analysis of Past Performance

Type Stock
Historic Profit -8.42%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 222.56M USD
Price to earnings Ratio -
1Y Target Price 4.27
Price to earnings Ratio -
1Y Target Price 4.27
Volume (30-day avg) 8
Beta 2.44
52 Weeks Range 2.03 - 7.05
Updated Date 08/15/2025
52 Weeks Range 2.03 - 7.05
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.96

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.26
Actual -0.23

Profitability

Profit Margin -64.23%
Operating Margin (TTM) -59.63%

Management Effectiveness

Return on Assets (TTM) -22.4%
Return on Equity (TTM) -57.1%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 161631275
Price to Sales(TTM) 2.92
Enterprise Value 161631275
Price to Sales(TTM) 2.92
Enterprise Value to Revenue 2.12
Enterprise Value to EBITDA -4.25
Shares Outstanding 52367400
Shares Floating 28843941
Shares Outstanding 52367400
Shares Floating 28843941
Percent Insiders 20.61
Percent Institutions 52.73

ai summary icon Upturn AI SWOT

Sight Sciences Inc

stock logo

Company Overview

overview logo History and Background

Sight Sciences Inc. was founded in 2011 and is focused on developing and commercializing innovative surgical and nonsurgical technologies intended to transform care and improve outcomes for patients with ophthalmic diseases. They have grown through product development and commercialization.

business area logo Core Business Areas

  • Glaucoma: Developing and marketing devices to address glaucoma, including the OMNI Surgical System and VISCO 360 Viscosurgical System, aimed at reducing intraocular pressure.
  • Dry Eye: Focused on technologies such as TearCare System, designed for the treatment of dry eye disease via localized heat therapy and meibomian gland expression.

leadership logo Leadership and Structure

Paul Badawi serves as the Chief Executive Officer. The company has a board of directors and operates with functional teams across R&D, sales, marketing, and operations.

Top Products and Market Share

overview logo Key Offerings

  • OMNI Surgical System: A microinvasive glaucoma surgery (MIGS) device used to reduce intraocular pressure in patients with glaucoma. Market share data is not explicitly public, but it's a competitive market with established players such as Glaukos (GKOS) and Ivantis. Competitors: Glaukos (GKOS), Ivantis, Alcon (ALC).
  • TearCare System: A device used for the treatment of dry eye disease. It applies controlled heat to the meibomian glands to improve gland function. Competitors include Johnson & Johnson Vision (JJNJ), Lumenis, and Allergan (ABBV).

Market Dynamics

industry overview logo Industry Overview

The ophthalmic market is driven by an aging population and technological advancements in diagnostics and treatments. Glaucoma and dry eye represent significant areas of unmet need and market opportunity.

Positioning

Sight Sciences Inc. is positioned as an innovator in the ophthalmic surgical and nonsurgical space, focusing on novel approaches to treating glaucoma and dry eye. Their competitive advantage lies in their proprietary technology and targeted treatment solutions.

Total Addressable Market (TAM)

The TAM for glaucoma and dry eye treatments is estimated to be in the billions of dollars annually. Sight Sciences Inc. aims to capture a significant share of this market through expanding their product portfolio and market penetration.

Upturn SWOT Analysis

Strengths

  • Innovative Product Portfolio
  • Proprietary Technology
  • Strong Focus on Ophthalmic Diseases
  • Growing Revenue

Weaknesses

  • Limited Market Share Compared to Established Competitors
  • Dependence on Reimbursement Policies
  • Relatively small company size in market with large players
  • History of net losses

Opportunities

  • Expanding Product Applications
  • Entering New Geographic Markets
  • Strategic Acquisitions or Partnerships
  • Increasing Awareness of Dry Eye and Glaucoma

Threats

  • Competition from Larger, More Established Companies
  • Changes in Healthcare Regulations
  • Product Liability Risks
  • Economic Downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • ALC
  • GKOS
  • ABBV

Competitive Landscape

Sight Sciences Inc. faces competition from larger, more established companies with greater resources. Their advantage lies in their innovative technology, while their disadvantage is their relatively smaller size and limited market share.

Growth Trajectory and Initiatives

Historical Growth: Sight Sciences Inc. has demonstrated strong revenue growth in recent years, driven by increased adoption of their products.

Future Projections: Analysts project continued revenue growth for Sight Sciences Inc., driven by expanding market penetration and new product launches.

Recent Initiatives: Recent initiatives include expanding the sales force, launching new products, and pursuing strategic partnerships.

Summary

Sight Sciences Inc. is a growing company with innovative ophthalmic solutions, showing strong revenue growth but struggling with profitability. They operate in a competitive market and need to carefully manage expenses and secure reimbursement to achieve long-term success. Market penetration and continued innovation are key to competing with larger players. Maintaining sufficient cash to fund operations is essential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Website
  • Analyst Reports
  • Industry Publications

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on publicly available information. Actual results may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sight Sciences Inc

Exchange NASDAQ
Headquaters Menlo Park, CA, United States
IPO Launch date 2021-07-15
Co-Founder, President, CEO & Director Mr. Paul Badawi
Sector Healthcare
Industry Medical Devices
Full time employees 216
Full time employees 216

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.